Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay

A group of direct buyers of the cholesterol drug Niaspan scored a victory on Wednesday when a Pennsylvania federal judge approved their bid to move forward as a class with a pay-for-delay antitrust suit against Teva Pharmaceuticals Industries Ltd. and AbbVie Inc…

Read this piece in its entirety at Law360.


Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s